抗 PEG 产品参考文献
通过阅读文献发现关于我们聚乙二醇 (PEG) 产品的更多信息
下文列出了已发表论文的部分清单以及客户使用我们的抗 PEG RabMAb® 产品后给出的评价。
抗-聚乙二醇抗体 [PEG-B-47] (ab51257)
Toxicol Pathol 41:970-83 (2013).
Rudmann DG et al.
High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins.
Mol Cancer Ther 12:1816-28 (2013).
Hendriks BS et al.
ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect.
ACS Nano 6:8007-14 (2012).
Bitner BR et al.
Antioxidant carbon particles improve cerebrovascular dysfunction following traumatic brain injury.
Bioconjug Chem 23:485-99 (2012).
Sherman MR et al.
Role of the methoxy group in immune responses to mPEG-protein conjugates.
Bioconjug Chem 23:248-63 (2012).
Cong Y et al.
Site-specific PEGylation at histidine tags.
Shock 31:192-200 (2009).
Sakai H et al.
Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: profiles of hemoglobin-vesicle degradation and hematopoiesis for 14 days.
Mol Immunol. 2014 Feb;57(2):236-46
Saifer MG et al.
Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins.
J Control Release. 2013 Feb 10;165(3):183-90
Shiraishi K et al.
Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.
Bioconjug Chem. 2012 May 16;23(5):881-99.
Cheng TL et al.
Analytical measurement of PEGylated molecules.
Int J Nanomedicine. 2012;7:2557-71.
Oberoi HS et al.
Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice.
Soft Matter. 2014 Feb 14;10(6):831-9.
Schulz M et al.
Lateral surface engineering of hybrid lipid-BCP vesicles and selective nanoparticle embedding.
J Control Release. 2013 Nov 10;171(3):339-48.
Desale SS et al.
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer.
BioDrugs. 2014 Aug;28(4):393-402.
Pink A et al.
Purification, Characterization and Plasma Half-Life of PEGylated Soluble Recombinant Non-HA-Binding CD44.
J Immunol. 2013 Nov 1;191(9):4599-610.
Suchard SJ et al.
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.
Anal Bioanal Chem. 2012 Jan;402(3):1229-39.
Wang SJ et al.
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
Bioconjug Chem. 2010 Jul 21;21(7):1264-70.
Su YC et al.
Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies.
Integr Biol (Camb). 2014 Jul 21;6(8):766-80.
Myers DE et al.
CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.
Mol Pharm. 2012 May 7;9(5):1291-301.
Elliott VL et al.
Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies.
更多产品参考文献，请访问 ab51257 产品参考文献页。
抗-聚乙二醇抗体 [PEG-B-47b] (生物素) (ab53449)
Growth Horm IGF Res 23:114-9 (2013).
Jen J et al.
Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: a pharmacokinetic, safety and tolerability study.
J Control Release 165:183-90 (2013).
Shiraishi K et al.
Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.
J Immunol 191:4599-610 (2013).
Suchard SJ et al.
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.
Biomaterials 34:3846-57 (2013).
Zhang J et al.
Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.
Int J Nanomedicine 6:259-69 (2011).
Xie H et al.
Integrin avß3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy.
Anal Chem 82:6877-86 (2010).
Xu Y et al.
Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma.
Inflamm Bowel Dis. 2013 May;19(6):1224-31.
Ueda N et al.
The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.
更多产品参考文献，请访问 ab53449 产品参考文献页。
抗-聚乙二醇抗体 [PEG-2-128] (ab133471)
Mol Immunol 57:236-46 (2014).
Saifer MG et al.
Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins.
Bioconjug Chem. 2012 May 16;23(5):881-99.
Cheng TL et al.
Analytical measurement of PEGylated molecules.
更多产品参考文献，请访问 ab133471 产品参考文献页。
聚合二醇 （PEG) RabMab ELISA 试剂盒（ab138914)
J Interferon Cytokine Res 33:769-77 (2013).
Lee JI et al.
Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
Anal Chem 85:9630-7 (2013).
Liu Q et al.
Method for characterization of PEGylated bioproducts in biological matrixes.
Korean J Gastroenterol 58:107-10 (2011).
Tae HJ et al.
[A case of pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C].
Invest Ophthalmol Vis Sci 52:1392-403 (2011).
Peng S et al.
Claudin-19 and the barrier properties of the human retinal pigment epithelium.
Invest Ophthalmol Vis Sci 51:3216-25 (2010).
Peng S et al.
Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
For more product references, please visit ab138914 product reference page.
客户好评
“（ PEG RabMAb 一抗，ab53449）的亲和力相对较高（低 nM）意味着我们可以广泛清洗检测孔（不含 Tween 的 PBS），且不会去除特异性结合的抗体 - 从本质上来讲，这意味着我们的实验结果‘背景低’且‘信噪比高’。”
由 Abreview 提供 -